US 12,435,043 B2
Inhibitors of NLRP3 inflammasome
George Hartman, Lansdale, PA (US); Paul Humphries, Menlo Park, CA (US); and Kevin Edward Leif Wilhelmsen, Albany, CA (US)
Assigned to BioAge Labs, Inc., Richmond, CA (US)
Filed by George Hartman, Lansdale, PA (US); Paul Humphries, Menlo Park, CA (US); and Kevin Edward Leif Wilhelmsen, Albany, CA (US)
Filed on Jul. 17, 2023, as Appl. No. 18/353,370.
Application 18/353,370 is a division of application No. 17/701,856, filed on Mar. 23, 2022, granted, now 11,702,391.
Claims priority of provisional application 63/219,538, filed on Jul. 8, 2021.
Claims priority of provisional application 63/164,780, filed on Mar. 23, 2021.
Prior Publication US 2024/0051923 A1, Feb. 15, 2024
Int. Cl. A61K 31/4353 (2006.01); C07D 231/56 (2006.01); C07D 235/06 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01)
CPC C07D 231/56 (2013.01) [A61K 31/4353 (2013.01); C07D 235/06 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01)] 15 Claims
 
1. A method of treating inflammation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula VII:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
X, Y, and Z, together with the ring to which they are attached, form

OG Complex Work Unit Chemistry
Ring A is selected from the group consisting of C6-10 aryl, 5-10 membered heteroaryl, C3-10 cycloalkyl, and 4-10 membered heterocycloalkyl;
Ring B is selected from the group consisting of phenyl, 5-6 membered heteroaryl, C3-6 cycloalkyl, and 3-6 membered heterocycloalkyl;
alternatively, Ring B is absent and m is 0;
Ring D is pyridinyl;
R1 is selected from the group consisting of H, C1-6 alkyl, and C3-6 cycloalkyl, wherein alkyl and cycloalkyl are each optionally substituted with R6;
R2 and R3 are each independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, and 3-6 membered heterocycloalkyl;
each R4 is independently selected from the group consisting of C1-6 alkyl, halo, —OH, —OR6, C3-7 cycloalkyl, 3-7 membered heterocycloalkyl, and —COR6;
each R5 is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, halo, —CN, —COR6, and —SO2R6;
each R6 is independently selected from the group consisting of C1-6 alkyl, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl, —NH2, —NH(C1-6 alkyl), and —N(C1-6 alkyl)2;
each R9 is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkyl-OH, —OC1-6 alkyl, C1-6 alkyl-O—C1-6 alkyl, O(C3-6 cycloalkyl), halo, —CN, —OH, —NH2, —NH(C1-6 alkyl), and —N(C1-6 alkyl)2;
m is 0, 1, 2, or 3;
n is 0, 1, 2, or 3; and
p is 0, 1, 2, or 3.